Company Analysis
Sign in

ABVC BioPharma, Inc. (ABVC)

Nasdaq: ABVC · Pharmaceutical Preparations · Fremont, CA · filing with the SEC since 2002
Full chart Alerts Compare
Grade3.0
◀ Past 1.3● Present 3.6▶ Future 3.4
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$296,000
Net income-$7.9M-61.3%
Earnings per share$-0.39+7.1%
Operating cash flow-$3.0M-65.1%
Cash$681,480+174.4%
Debtn/a
Shareholders’ equity$11.1M+806.2%
Shares, diluted20.1M+72.3%
Return on equity-71.2%
The recordfrom its filings
Filings in 202628
Newest filingNov 12 · S-3/A
Annual reportMar 3, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted12
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$3.9MCash from operations -$2.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
15171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 2, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 29, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form PRER14A
Form PRER14A
Open the filing on sec.gov
Aug 27, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 25, 2026 · SEC EDGAR · Form PRER14A
Form PRER14A
Open the filing on sec.gov
Aug 17, 2026 · SEC EDGAR · Form 424B4
Offering prospectus
Open the filing on sec.gov
Aug 17, 2026 · SEC EDGAR · Form 424B4
Offering prospectus
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ABVC · research, not advice